Recent Updates
Recently added Catalysts
BDX

BD Acquires Tissuemed, Ltd. To Add Advanced Sealant To Its Portfolio Of Surgical Solutions BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired Tissuemed, Ltd., a...

Key Takeaway: FRANKLIN LAKES, N.J. , Dec. 9, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today it has acquired Tissuemed, Ltd., a privately held firm headquartered in Leeds, England that is an industry leader in d

Full Press Release Details

FRANKLIN LAKES, N.J. , Dec. 9, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today it has acquired Tissuemed, Ltd., a privately held firm headquartered in Leeds, England that is an industry leader in developing self-adhesive surgical sealant films.
"This advanced sealant serves as a strategic complement to the BD products used in the operating room today — providing us with the opportunity to equip surgeons with a more robust, highly-integrated portfolio of surgical solutions," said Kevin Kelly , president of Surgery for BD. "Integrating Tissuepatch ™ into our business aligns with our commitment to continuously innovate in our core portfolio to help support minimally invasive surgeries."
Tissuepatch ™ is already trusted among surgeons due to its design, which enables strong adhesive and minimal swelling. This foundation provides BD with an opportunity to leverage its reach and clinical expertise to continue to innovate within the sealant technology category, which is expected to grow significantly over the next five to 10 years.
Terms of the transaction were not disclosed. The transaction is expected to be immaterial to BD's fiscal 2022 financial results.
About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health ™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo .
Contacts:
Trey Hollern BD Public Relations
862.284.8629
[email protected] Nadia Goncalves BD Investor Relations 201.847.5934 [email protected]
SOURCE BD (Becton, Dickinson and Company)

21 %

Last updated: Dec 9, 2021